Gilead Wins Appeals Court Ruling Blocking HIV Drug Imports
A federal appeals court affirmed a preliminary injunction on Thursday that favors Gilead Sciences, preventing multiple companies from importing its HIV treatments through international channels and supplying them to U.S. patients via employer health plans. This ruling, as reported by CNBC, marks a crucial win for Gilead, which contended that the importation practice infringed on its patents and regulatory approvals. The decision jeopardizes the sustainability of international prescription drug programs aimed at lowering costs for American patients. This case underscores the ongoing conflict between pharmaceutical companies' intellectual property rights and the push for more affordable medications. The injunction will remain effective as the underlying lawsuit continues, reinforcing Gilead's market exclusivity for its HIV medications in the U.S.
Key facts
- Gilead Sciences won a federal appeals court ruling on Thursday.
- The ruling upholds a preliminary injunction blocking companies from importing Gilead's HIV medications.
- The imported drugs were intended for distribution to U.S. patients via employer health plans.
- The injunction was originally granted in a lower court.
- The appeals court decision was reported by CNBC.
- The ruling threatens overseas prescription drug programs.
- Gilead's stock ticker is $GILD.
- The case involves patent and regulatory issues.
Entities
Institutions
- Gilead Sciences
- CNBC
Sources
- Quartz —